Cite
Pembrolizumab Interferes with the Differentiation of Human FOXP3+-Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR.
MLA
Nair, Varun Sasidharan, et al. “Pembrolizumab Interferes with the Differentiation of Human FOXP3+-Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of MTOR.” Journal of Immunology, vol. 204, no. 1, Jan. 2020, pp. 199–211. EBSCOhost, https://doi.org/10.4049/jimmunol.1900575.
APA
Nair, V. S., Toor, S. M., Taouk, G., Pfister, G., Ouararhni, K., Alajez, N. M., & Elkord, E. (2020). Pembrolizumab Interferes with the Differentiation of Human FOXP3+-Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR. Journal of Immunology, 204(1), 199–211. https://doi.org/10.4049/jimmunol.1900575
Chicago
Nair, Varun Sasidharan, Salman M. Toor, Ghina Taouk, Gerald Pfister, Khalid Ouararhni, Nehad M. Alajez, and Eyad Elkord. 2020. “Pembrolizumab Interferes with the Differentiation of Human FOXP3+-Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of MTOR.” Journal of Immunology 204 (1): 199–211. doi:10.4049/jimmunol.1900575.